Provided by Tiger Trade Technology Pte. Ltd.

Avis Budget

146.88
+0.27000.18%
Post-market: 146.880.00000.00%19:40 EDT
Volume:260.36K
Turnover:38.39M
Market Cap:5.19B
PE:-8.19
High:149.85
Open:146.39
Low:146.39
Close:146.61
52wk High:847.70
52wk Low:85.96
Shares:35.32M
Float Shares:14.85M
Volume Ratio:1.03
T/O Rate:1.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.9408
EPS(LYR):-25.2557
ROE:5800.00%
ROA:2.70%
PB:-1.53
PE(LYR):-5.82

Loading ...

Park24 to Reintroduce Shareholder Benefits Tied to Times CAR Service

TIPRANKS
·
Jun 15

CARsgen Advances Allogeneic CAR T Programs After Positive Early Data at EHA 2026

TIPRANKS
·
Jun 15

Legend Biotech announces first clinical proof-of-concept data for LB2501

TIPRANKS
·
Jun 15

GenScript Associate Legend Biotech Reports Promising In Vivo CAR-T Data in B-Cell Lymphoma

TIPRANKS
·
Jun 14

Genscript Biotech's Affiliate Reports Proof of Concept for Novel In Vivo Dual-Target CAR-T Therapy in Lymphoma

Stock News
·
Jun 14

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

GlobeNewswire
·
Jun 14

Avis Budget Issues New Asset-Backed Securities for Fleet Funding

TIPRANKS
·
Jun 13

Avis Budget unit issues USD 650 million in vehicle-backed notes under AESOP program

Reuters
·
Jun 13

Caribou Biosciences: Buy Rating Reaffirmed on Advancing Allogeneic CAR-T Pipeline and EHA Data; $6 Price Target Maintained

TIPRANKS
·
Jun 12

Caribou Biosciences presents ANTLER trial results at EHA

TIPRANKS
·
Jun 11

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

GlobeNewswire
·
Jun 11

Cellectis Unveils Strong Early CAR-T Data for Lasme-cel and Eti-cel at EHA 2026

TIPRANKS
·
Jun 11

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

GlobeNewswire
·
Jun 11

Verra Mobility Faces Federal Securities Lawsuit After 71% Stock Drop Following Avis Budget Group Termination Notice

TIPRANKS
·
Jun 11

Cellectis Gains FDA RMAT Status for Allogeneic CAR-T lasme-cel in r/r B-ALL

TIPRANKS
·
Jun 10

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

GlobeNewswire
·
Jun 10

Avis Budget Group Is Maintained at Underweight by JP Morgan

Dow Jones
·
Jun 09

What Cencora (COR)'s Expanded Role in Kite CAR T Distribution Means For Shareholders

Simply Wall St.
·
Jun 09

Cartesian Therapeutics Announces In Vivo CAR-T Licensing Alliance

TIPRANKS
·
Jun 09

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

GlobeNewswire
·
Jun 09